Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer.

Summary— The ability of serum prostate specific antigen (PSA) to predict bone metastases at initial presentation was determined in 146 patients, and in 66 patients during a 3-year period; 14.7% of patients with bone metastases at presentation had a PSA value less than 20 ng/ml. All patients who subsequently developed bone metastases had a PSA greater than 20 ng/ml and the rise in PSA often antedated the detection of bone metastases. Bone scans are still necessary in the initial staging but following diagnosis and treatment can be replaced by serum PSA measurement in monitoring patients with prostatic cancer.

[1]  W. Catalona,et al.  Clinical use of prostate specific antigen in patients with prostate cancer. , 1989, The Journal of urology.

[2]  R. Shearer.  Prostatic specific antigen. , 1991, British journal of urology.

[3]  N. Yang,et al.  Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. , 1985, Cancer research.

[4]  J. Oesterling,et al.  Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. , 1988, The Journal of urology.

[5]  T. Stamey,et al.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. , 1989, The Journal of urology.

[6]  J. Fitzpatrick,et al.  Serial bone scanning: the assessment of treatment response in carcinoma of the prostate. , 1978, British journal of urology.

[7]  J. Oesterling,et al.  Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared. , 1987, Clinical chemistry.

[8]  D. Newling,et al.  An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate. , 1986, European urology.

[9]  P. Lange,et al.  Serum prostate-specific antigen: its use in diagnosis and management of prostate cancer. , 1989, Urology.

[10]  Controversies in management of apparently localized carcinoma of prostate. , 1989, Urology.

[11]  G. Murphy,et al.  Use of human prostate-specific antigen in monitoring prostate cancer. , 1981, Cancer research.

[12]  G. Murphy,et al.  Purification of a human prostate specific antigen. , 1979, Investigative urology.

[13]  R L Vessella,et al.  Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. , 1987, The Journal of urology.